CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome

Nature Biotechnology

Volumn 35, Issue 6, 2017, Pages 561-568

  Klann, Tyler S ^a,b   Black, Joshua B ^a,b   Chellappan, Malathi ^a,b   Safi, Alexias ^b   Song, Lingyun ^b   Hilton, Isaac B ^a,b   Crawford, Gregory E ^b,c   Reddy, Timothy E ^a,b,c   Gersbach, Charles A ^a,b,c  

^a Duke University   (United States)

^b DUKE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENES;

BIOLOGICAL PROCESS; EDITING TECHNOLOGY; FUNCTIONAL ANNOTATION; GAIN-OF FUNCTION; GENOME-WIDE ASSOCIATION STUDIES; HIGH THROUGHPUT; HIGH THROUGHPUT SCREENING; REGULATORY ELEMENTS;

THROUGHPUT;

BLASTICIDIN S; DEOXYRIBONUCLEASE I; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; GUIDE RNA; HEMOGLOBIN BETA CHAIN; MESSENGER RNA; TRASTUZUMAB; CASPASE 9;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; EPIGENETIC REPRESSION; EPIGENETICS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GAIN OF FUNCTION MUTATION; GENE EDITING; GENE REPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; UPREGULATION; CHROMOSOMAL MAPPING; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN GENOME; PROCEDURES; REGULATORY SEQUENCE;

CASPASE 9; CHROMOSOME MAPPING; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; EPIGENOMICS; GENE EDITING; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; REGULATORY ELEMENTS, TRANSCRIPTIONAL; SEQUENCE ANALYSIS, DNA;

EID: 85020467141     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3853     Document Type: Article

References (56)

1. Thurman, R.E., et al. The accessible chromatin landscape of the human genome. Nature 489, 75-82 (2012).
2. Hindorff, L.A., Junkins, H.A., Mehta, J.P., Manolio, T.A. A Catalog of Published Genome-Wide Association Studies. http://www.genome.gov/gwastudies (2009).
3. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
4. Bernstein, B.E., et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat. Biotechnol. 28, 1045-1048 (2010).
5. Arnold, C.D., et al. Genome-wide quantitative enhancer activity maps identified by STARR-seq. Science 339, 1074-1077 (2013).
6. Vockley, C.M., et al. Massively parallel quantification of the regulatory effects of noncoding genetic variation in a human cohort. Genome Res. 25, 1206-1214 (2015).
7. Vockley, C.M., et al. Direct GR binding sites potentiate clusters of TF binding across the human genome. Cell 166, 1269-1281 (2016).
8. Barrangou, R., Doudna, J.A. Applications of CRISPR technologies in research and beyond. Nat. Biotechnol. 34, 933-941 (2016).
9. Jinek, M., et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
10. Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
11. Mali, P., et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
12. Cho, S.W., Kim, S., Kim, J.M., Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230-232 (2013).
13. Shalem, O., et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84-87 (2014).
14. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
15. Koike-Yusa, H., Li, Y., Tan, E.P., Del Castillo Velasco-Herrera, M., Yusa, K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32, 267-273 (2014).
16. Canver, M.C., et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192-197 (2015).
17. Korkmaz, G., et al. Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat. Biotechnol. 34, 192-198 (2016).
18. Rajagopal, N., et al. High-throughput mapping of regulatory DNA. Nat. Biotechnol. 34, 167-174 (2016).
19. Diao, Y., et al. A new class of temporarily phenotypic enhancers identified by CRISPR/Cas9-mediated genetic screening. Genome Res. 26, 397-405 (2016).
20. Sanjana, N.E., et al. High-resolution interrogation of functional elements in the noncoding genome. Science 353, 1545-1549 (2016).
21. Vierstra, J., et al. Functional footprinting of regulatory DNA. Nat. Methods 12, 927-930 (2015).
22. Housden, B.E., et al. Loss-of-function genetic tools for animal models: Cross-species and cross-platform differences. Nat. Rev. Genet. 18, 24-40 (2017).
23. Thakore, P.I., Black, J.B., Hilton, I.B., Gersbach, C.A. Editing the epigenome: Technologies for programmable transcription and epigenetic modulation. Nat. Methods 13, 127-137 (2016).
24. Qi, L.S., et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013).
25. Gilbert, L.A., et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442-451 (2013).
26. Gao, X., et al. Reprogramming to pluripotency using designer TALE transcription factors targeting enhancers. Stem Cell Reports 1, 183-197 (2013).
27. Gao, X., et al. Comparison of TALE designer transcription factors and the CRISPR/dCas9 in regulation of gene expression by targeting enhancers. Nucleic Acids Res. 42, e155 (2014).
28. Gilbert, L.A., et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647-661 (2014).
29. Konermann, S., et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583-588 (2015).
30. Hilton, I.B., et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol. 33, 510-517 (2015).
31. Kearns, N.A., et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat. Methods 12, 401-403 (2015).
32. Thakore, P.I., et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 12, 1143-1149 (2015).
33. Xu, X., et al. A CRISPR-based approach for targeted DNA demethylation. Cell Discov. 2, 16009 (2016).
34. Choudhury, S.R., Cui, Y., Lubecka, K., Stefanska, B., Irudayaraj, J. CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. Oncotarget 7, 46545-46556 (2016).
35. Vojta, A., et al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation. Nucleic Acids Res. 44, 5615-5628 (2016).
36. Mali, P., et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013).
37. Liu, X.S., et al. Editing DNA methylation in the mammalian genome. Cell 167, 233-247 (2016).
38. Boyle, A.P., et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 132, 311-322 (2008).
39. Sabo, P.J., et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat. Methods 3, 511-518 (2006).
40. Hardison, R., et al. Locus control regions of mammalian ?-globin gene clusters: Combining phylogenetic analyses and experimental results to gain functional insights. Gene 205, 73-94 (1997).
41. Baron, M.H. Developmental regulation of the vertebrate globin multigene family. Gene Expr. 6, 129-137 (1996).
42. Dean, A., Ley, T.J., Humphries, R.K., Fordis, M., Schechter, A.N. Inducible transcription of five globin genes in K562 human leukemia cells. Proc. Natl. Acad. Sci. USA 80, 5515-5519 (1983).
43. Song, L., et al. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. Genome Res. 21, 1757-1767 (2011).
44. Vu, T., Claret, F.X. Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2, 62 (2012).
45. Slamon, D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
46. Gajria, D., Chandarlapaty, S. HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev. Anticancer Ther. 11, 263-275 (2011).
47. Hurtado, A., et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663-666 (2008).
48. Chu, P.-Y., Li, T.-K., Ding, S.-T., Lai, I.R., Shen, T.-L. EGF-induced Grb7 recruits and promotes Ras activity essential for the tumorigenicity of Sk-Br3 breast cancer cells. J. Biol. Chem. 285, 29279-29285 (2010).
49. Fulco, C.P., et al. Systematic mapping of functional enhancer-promoter connections with CRISPR interference. Science 354, 769-773 (2016).
50. Findlay, G.M., Boyle, E.A., Hause, R.J., Klein, J.C., Shendure, J. Saturation editing of genomic regions by multiplex homology-directed repair. Nature 513, 120-123 (2014).
51. Sanjana, N.E., Shalem, O., Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783-784 (2014).
52. Song, L., Crawford, G.E. DNase-seq: A high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells. Cold Spring Harb. Protoc. 2010, pdb.prot5384 (2010).
53. O'Brien, A., Bailey, T.L. GT-Scan: Identifying unique genomic targets. Bioinformatics 30, 2673-2675 (2014).
54. Salmon, P., Trono, D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. Chapter 4, Unit 4.21 (2006).
55. Langmead, B., Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357-359 (2012).
56. Love, M.I., Huber, W., Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).